Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AHS 2022 | Future directions in migraine prevention treatment

Rami Apelian • 21 Jun 2022
AHS 2022
Headache

Rami Apelian, MD, MPH, FAES, Huntington Headache and Neurology, Arcadia, CA, discusses future directions in migraine prevention treatment. Moving forward, Dr Apelian is investigating new drugs targeting CGRP, utilizing different delivery mechanisms. Furthermore, there is also an incentive to investigate abortive and preventive drugs that target other aspects of the transmission system. This would provide patients with more targeted therapy, helping their individual needs. This interview took place during the 2022 American Headache Society (AHS) Meeting in Denver, CO.

Disclosures

Rami Apelian received compensation as a consultant/speaker for Lundbeck, Lilly, Teva, Abbvie, and Biohaven

More from Rami Apelian

Eptinezumab: the first approved infusion medication for migraine prevention
1:06
Eptinezumab: the first approved infusion medication for migraine prevention
Rami Apelian • 21 Jun 2022
Differences and similarities between PROMISE-1 & PROMISE-2
1:10
Differences and similarities between PROMISE-1 & PROMISE-2
Rami Apelian • 21 Jun 2022
Safety of eptinezumab in migraine patients
1:34
Safety of eptinezumab in migraine patients
Rami Apelian • 21 Jun 2022
PROMISE-1 & PROMISE-2: eptinezumab in episodic and chronic migraine
1:08
PROMISE-1 & PROMISE-2: eptinezumab in episodic and chronic migraine
Rami Apelian • 21 Jun 2022

Related Videos

PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
TRIPLE study: triple combination therapy for chronic migraine
2:41
TRIPLE study: triple combination therapy for chronic migraine
Marina Romozzi • 27 Jun 2026
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
5:05
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
Richard Lipton • 1 Jul 2026
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
8:49
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
Richard Lipton • 1 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals